Callan Capital LLC Purchases 4,685 Shares of Sanofi (NASDAQ:SNY)

Callan Capital LLC boosted its position in Sanofi (NASDAQ:SNY) by 90.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 9,852 shares of the company’s stock after purchasing an additional 4,685 shares during the period. Callan Capital LLC’s holdings in Sanofi were worth $478,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UBS Group AG raised its stake in shares of Sanofi by 5.1% during the 4th quarter. UBS Group AG now owns 934,635 shares of the company’s stock worth $46,479,000 after purchasing an additional 45,175 shares during the period. Corient Private Wealth LLC raised its position in Sanofi by 62.1% in the fourth quarter. Corient Private Wealth LLC now owns 169,494 shares of the company’s stock worth $8,429,000 after acquiring an additional 64,949 shares during the period. Assetmark Inc. boosted its stake in Sanofi by 7.1% in the fourth quarter. Assetmark Inc. now owns 84,426 shares of the company’s stock valued at $4,199,000 after acquiring an additional 5,578 shares during the last quarter. Frazier Financial Advisors LLC bought a new position in shares of Sanofi during the 4th quarter valued at approximately $28,000. Finally, Cypress Asset Management Inc. TX purchased a new stake in shares of Sanofi during the 4th quarter worth approximately $508,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Sanofi stock opened at $57.63 on Friday. The firm has a market capitalization of $145.96 billion, a P/E ratio of 28.96, a PEG ratio of 1.62 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The business has a fifty day moving average price of $54.34 and a 200-day moving average price of $50.48.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the previous year, the firm earned $0.95 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. As a group, equities research analysts forecast that Sanofi will post 4.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.